EyePoint (EYPT) Akcija Cena
EyePoint Cena
Ieņēmumi auga par 17,5 % gadā pēdējos 19 gados līdz 31,37 M USD. EyePoint neto marža tagad ir -739,4 %, samazinājusies no -158,1 % pirms dažiem gadiem.
EyePoint akcijas cena
Iegūstiet šos datus caur Eulerpool API
100 000 pieprasījumu/mēn. bez maksas · bez kartes
EyePoint biznesa modelis un akciju analīze
Bieži uzdotie jautājumi par EyePoint akciju
EyePoint Pharmaceuticals Inc is a biopharmaceutical company specializing in the development and commercialization of innovative ophthalmic products. The business model of EyePoint Pharmaceuticals Inc revolves around developing sustained-release drug delivery systems for the treatment of serious eye diseases. By utilizing its proprietary technologies, the company aims to improve patients' outcomes by providing long-lasting and targeted drug delivery options. EyePoint Pharmaceuticals Inc focuses on developing and commercializing products addressing unmet medical needs, ultimately enhancing the quality of life for individuals suffering from various eye conditions.
EyePoint Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of EyePoint Pharmaceuticals Inc in the market are Aerie Pharmaceuticals Inc and Ocular Therapeutix Inc.
EyePoint Pharmaceuticals Inc is a renowned pharmaceutical company specializing in developing and commercializing innovative ophthalmic products. Founded in 1987, EyePoint has a rich history of advancing patient care in the field of ophthalmology. With a strong focus on sustained-release drug delivery systems, the company has successfully developed and received regulatory approvals for several cutting-edge ophthalmic treatments. EyePoint Pharmaceuticals Inc continues to thrive as a leading player in the industry, catering to the needs of patients worldwide. With its commitment to innovation and improving eye health, EyePoint Pharmaceuticals Inc has become a trusted name in the pharmaceutical sector.
EyePoint Pharmaceuticals Inc has achieved several significant milestones in its history. The company has successfully developed and commercialized innovative ophthalmic treatments, making a positive impact on patient care. EyePoint Pharmaceuticals Inc received FDA approval for its sustained-release intraocular implant, DEXYCU®, which is used for treating inflammation after cataract surgery. Additionally, the company gained FDA approval for YUTIQ®, a micro-insert used for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. These milestones demonstrate EyePoint Pharmaceuticals Inc's commitment to advancing therapeutic options in the field of ophthalmology.
EyePoint Pharmaceuticals Inc is primarily present in several countries and regions. These include the United States, where the company is headquartered, as well as Europe, specifically Germany, France, and the United Kingdom. Additionally, EyePoint Pharmaceuticals Inc has a presence in selected markets in Asia, including Japan. With its global reach, EyePoint Pharmaceuticals Inc aims to bring innovative ophthalmic products and therapies to patients worldwide.
EyePoint Pharmaceuticals Inc represents a strong commitment to improving patient outcomes through advanced ophthalmic therapeutic solutions. With a focus on innovation, the company is dedicated to developing and commercializing sustained-release drug delivery technologies. EyePoint Pharmaceuticals strives to address unmet medical needs and provide convenient treatment options to patients suffering from serious eye conditions. By leveraging its expertise and cutting-edge research, EyePoint Pharmaceuticals aims to enhance the quality of life for individuals worldwide.
19 analītiķi pašlaik vērtē EyePoint akciju: 13 iesaka pirkt, 6 turēt un 0 pārdot. 2026. gadam analītiķi sagaida, ka EyePoint gūs 1,72 M USD ieņēmumus un -2,52 USD peļņu uz akciju.
Pēc pašreizējā kursa EyePoint akcija maksā 2,72 EUR (3,05 USD).
EyePoint akcija (EYPT) tiek kotēta 3 biržās, tostarp: NASDAQ (EYPT), Frankfurt (PV3B.F), München (PV3B.MU).
EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that develops and markets innovative drugs for body tissues and eye diseases. The company's business model focuses on the development, manufacturing, and marketing of therapeutics for chronic eye diseases such as macular degeneration, diabetic retinopathy, and uveitis. EyePoint Pharmaceuticals specializes in strategic partnerships and collaborations with renowned pharmaceutical companies and global organizations. The company offers drug solutions such as Iluvien, used for the treatment of macular degeneration, and Yutiq, intended for chronic uveitis therapy. Iluvien is a steroid implant composed of a unique formulation of fluocinolone acetonide (FAc) and a biopolymer that slowly degrades during use. It has a unique ability to exert a sustained effect on eye disease, significantly reducing the need for repeated intravitreal injections. Iluvien is approved in Europe and Canada and has been submitted to the US Food and Drug Administration (FDA). Yutiq is a steroid implant developed for the treatment of chronic uveitis. It is implanted into the posterior chamber of the eye and releases the active ingredient triamcinolone acetonide (TAc) to reduce inflammation. Yutiq has been approved by the FDA and is currently available in the United States. In addition, EyePoint Pharmaceuticals also offers Dexpel, a technology platform for long-lasting surgical implants. This platform can be utilized in various medical fields such as oncology, orthopedics, and neurosurgery to control drug release, prolong treatment duration, and reduce the need for repeated injections. EyePoint Pharmaceuticals also pursues a diversification strategy to expand its product portfolio and create stable growth. This includes collaborating with other companies to provide technology solutions and services tailored to the needs of customers. Overall, the business model of EyePoint Pharmaceuticals aims to bring innovative drugs to the market that enable effective treatment of eye diseases and significantly improve patients' quality of life. The company relies on a combination of well-established and innovative technologies to control drug release and ensure optimal therapy.
gaidāmā apgrozījums EyePoint ir 1,72 M USD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.
gaidāmā peļņa EyePoint ir -209,36 M USD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.
EyePoint cenas un peļņas rādītājs (P/E) pašlaik ir -1,21. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt EyePoint akcijas vērtību.
EyePoint cenas un apgrozījuma rādītājs (P/S) pašlaik ir 147,13. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā EyePoint akcijas vērtības mērs.
EyePoint Eulerpool kvalitātes rādītājs ir 2/10.
EyePoint ISIN ir US30233G2093. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.
EyePoint WKN ir A2QJRU. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.
EyePoint tikeris ir EYPT. Tikeris tiek izmantots EyePoint akciju tirdzniecībai biržā.
EyePoint akcija
EyePoint Salīdzināmo uzņēmumu grupa
EyePoint Biržas kods
EyePoint FIGI
Visi EyePoint fundamentālie rādītāji un padziļinātā analīze
Mūsu akciju analīze par EyePoint ietver svarīgus finanšu rādītājus, piemēram, apgrozījumu, peļņu, P/E rādītāju, P/S rādītāju, EBIT, kā arī informāciju par dividendēm. Turklāt mēs aplūkojam aspektus kā akcijas, tirgus kapitalizāciju, parādus, pašu kapitālu un saistības no EyePoint. Ja meklējat sīkāku informāciju par šīm tēmām, piedāvājam detalizētas analīzes mūsu apakšlapās: